Randox introduces new drugs of abuse test

Randox Laboratories has released a second biochip for drugs of abuse DoA urine screening.

It claims that the new DoA Array II simultaneously tests for ten drugs in a single procedure, using only one sample.

The biochip is also able to screen for six opoid analgesics including Fentanyl, Ketamine, LSD, Methaqualone and Ecstasy.

The DoA Array II’s introduction follows the success of its predecessor, the DoA Array I test for Barbiturates, Amphetamines, Cocaine, Opiates and Cannaboids.

It incorporates a charge-coupled device camera which detects the chemiluminescent signal generated by each test region and advanced image-processing software which reads all ten test results simultaneously.

Both arrays can also include an eleventh test, creatinine, designed to identify adulterate urine samples.

According to Randox, the DoA screening procedure offers a "rapid consistent and cost-effective" method of testing for drugs of abuse.

The international diagnostics company is currently developing blood and oral fluid biochips to be used in drugs testing, as currently both arrays are only available for urine screening.